These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33557653)

  • 21. Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis.
    Vonghia L; Michielsen P; Francque S
    Int J Mol Sci; 2013 Oct; 14(10):19867-90. PubMed ID: 24084730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.
    Luci C; Bourinet M; Leclère PS; Anty R; Gual P
    Front Endocrinol (Lausanne); 2020; 11():597648. PubMed ID: 33384662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophages as Key Players during Adipose Tissue-Liver Crosstalk in Nonalcoholic Fatty Liver Disease.
    Korf H; Boesch M; Meelberghs L; van der Merwe S
    Semin Liver Dis; 2019 Jul; 39(3):291-300. PubMed ID: 31041786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological mechanisms and therapeutic targets of fatty liver diseases.
    Wang H; Mehal W; Nagy LE; Rotman Y
    Cell Mol Immunol; 2021 Jan; 18(1):73-91. PubMed ID: 33268887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. OX40 Regulates Both Innate and Adaptive Immunity and Promotes Nonalcoholic Steatohepatitis.
    Sun G; Jin H; Zhang C; Meng H; Zhao X; Wei D; Ou X; Wang Q; Li S; Wang T; Sun X; Shi W; Tian D; Liu K; Xu H; Tian Y; Li X; Guo W; Jia J; Zhang Z; Zhang D
    Cell Rep; 2018 Dec; 25(13):3786-3799.e4. PubMed ID: 30590049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.
    Machado MV; Michelotti GA; Pereira Tde A; Boursier J; Kruger L; Swiderska-Syn M; Karaca G; Xie G; Guy CD; Bohinc B; Lindblom KR; Johnson E; Kornbluth S; Diehl AM
    Gut; 2015 Jul; 64(7):1148-57. PubMed ID: 25053716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview.
    Parthasarathy G; Revelo X; Malhi H
    Hepatol Commun; 2020 Apr; 4(4):478-492. PubMed ID: 32258944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis.
    Tomita K; Freeman BL; Bronk SF; LeBrasseur NK; White TA; Hirsova P; Ibrahim SH
    Sci Rep; 2016 Jun; 6():28786. PubMed ID: 27349927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophages in the pathophysiology of NAFLD: The role of sex differences.
    Ministrini S; Montecucco F; Sahebkar A; Carbone F
    Eur J Clin Invest; 2020 Jun; 50(6):e13236. PubMed ID: 32294235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease.
    Lee J; Park JS; Roh YS
    Arch Pharm Res; 2019 Nov; 42(11):935-946. PubMed ID: 31571145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4
    Zhou Y; Zhang H; Yao Y; Zhang X; Guan Y; Zheng F
    Front Immunol; 2022; 13():967410. PubMed ID: 36032141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In Vitro Human Liver Model of Nonalcoholic Steatohepatitis by Coculturing Hepatocytes, Endothelial Cells, and Kupffer Cells.
    Suurmond CE; Lasli S; van den Dolder FW; Ung A; Kim HJ; Bandaru P; Lee K; Cho HJ; Ahadian S; Ashammakhi N; Dokmeci MR; Lee J; Khademhosseini A
    Adv Healthc Mater; 2019 Dec; 8(24):e1901379. PubMed ID: 31746151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.
    Cai J; Zhang XJ; Li H
    Trends Endocrinol Metab; 2018 Oct; 29(10):712-722. PubMed ID: 30131212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Nonalcoholic Steatohepatitis on a Chip.
    Freag MS; Namgung B; Reyna Fernandez ME; Gherardi E; Sengupta S; Jang HL
    Hepatol Commun; 2021 Feb; 5(2):217-233. PubMed ID: 33553970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress.
    Sakaguchi S; Takahashi S; Sasaki T; Kumagai T; Nagata K
    Drug Metab Pharmacokinet; 2011; 26(1):30-46. PubMed ID: 21150132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.